Prevention of cardiotoxicity among survivors of childhood cancer.

Related Articles

Prevention of cardiotoxicity among survivors of childhood cancer.

Br J Clin Pharmacol. 2017 Mar;83(3):455-465

Authors: Hutchins KK, Siddeek H, Franco VI, Lipshultz SE

Abstract
LINKED ARTICLES: This article is part of a joint Themed section with the British Journal of Pharmacology on Cardiotoxicity. The rest of the Themed section will appear in a future issue of BJP and will be available at http://ift.tt/2Czj93T The number of survivors of childhood cancers has increased exponentially over the past few decades. However, these survivors are also at substantially increased long-term risk of morbidity and mortality, especially from treatment-related cardiotoxicity. Preventing these risks is now a priority when treating children and adolescents with cancer. Dexrazoxane reduces the risk of anthracycline-induced cardiotoxicity among adults and children with cancer without reducing its antineoplastic effects or event-free survival. Thus, it should be strongly considered as a part of therapy for children and adolescents treated with anthracyclines.

PMID: 27591829 [PubMed - indexed for MEDLINE]

http://ift.tt/2D08j88